Iovance Biotherapeutics
IOVA
IOVA
139 hedge funds and large institutions have $1.05B invested in Iovance Biotherapeutics in 2018 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 28 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
6% more funds holding
Funds holding: 131 → 139 (+8)
1.59% more ownership
Funds ownership: 94.66% → 96.25% (+1.6%)
3% more capital invested
Capital invested by funds: $1.02B → $1.05B (+$30.8M)
Holders
139
Holding in Top 10
8
Calls
$1.53M
Puts
$567K
Top Buyers
| 1 | +$43.8M | |
| 2 | +$27.4M | |
| 3 | +$18.8M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.3M |
Top Sellers
| 1 | -$15M | |
| 2 | -$5.11M | |
| 3 | -$4.24M | |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$4.07M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.66M |